EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Factors Affecting the Safety and Effectiveness of Venom Immunotherapy

L Arzt-Gradwohl, SA Herzog, W Aberer, T Alfaya Arias, D Antolín-Amérigo, P Bonadonna, E Boni, A Bożek, M Chełmińska, B Ebner, N Frelih, R Gawlik, A Gelincik, T Hawranek, W Hoetzenecker, A Jiménez Blanco, K Kita, R Kendirlinan, M Košnik, K Laipold, R Lang, F Marchi, M Mauro, M Nittner-Marszalska, I Poziomkowska-Gęsicka, V Pravettoni, D Preziosi, J Stoevesandt, A Trautmann, M Vachová, GJ Sturm

Journal of Investigational Allergy and Clinical Immunology · 2025-02-17 · 35 (1) · 40-49

DOI: 10.18176/jiaci.0967 ↗
AbstractBibliografische Angaben

Abstract

Background: The safety profile of venom immunotherapy (VIT) is a relevant issue, and considerable differences have been reported in the safety and efficacy of this treatment modality. The primary aim of this study was to evaluate the safety of angiotensin-converting enzyme inhibitors and ß-blockers during VIT. In a second analysis, we evaluated data on premedication and venom preparations and their association with systemic adverse events (AEs) during the up-dosing phase and the first year of the maintenance phase, as well as the outcome of field stings and sting challenges. Methods: Ours was an open, prospective, observational, multicenter study that recruited 1425 patients, of whom 1342 underwent VIT. Results: Premedication with oral antihistamines was taken by 52.1% of patients during up-dosing and 19.7% of patients during the maintenance phase. Antihistamines had no effect on the frequency of systemic AEs (P=.11), although large local reactions (LLRs) were less frequent (OR, 0.74; 95%CI, 0.58-0.96; P=.02). Aqueous preparations were preferred for up-dosing (73.0%), and depot preparations were used for the maintenance phase (64.5%). The type of venom preparation had no influence on the frequency of systemic AEs or on the effectiveness of VIT (P=.26 and P=.80, respectively), while LLRs were less frequent with depot preparations (P

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →